Granted Janssen was a much much bigger deal but Genetech have marginally increased the cashflow to company at a less advanced stage.
Janssen went Licensing Agreement - Extension - Expansion - Walk for $2.3m Genentech have gone Research Agreement - Licensing Agreement - Extension for $2.5m.
Also worth noting i guess as a whole Roche / Genrntech have contributed more through earlier and expired agreements in a different area of focus. Roche was alwsys pretty tight on the numbers but i think it was about $500k over 3 years targetting the blood brain barrier & delivery. So i guess you could say $3m in total ?
Granted Janssen was a much much bigger deal but Genetech have...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13987 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 1380 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |